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ABSTRACT A novel influenza A virus (IAV) of the H7N9 subtype has been isolated from severely diseased patients with pneumo-
nia and acute respiratory distress syndrome and, apparently, from healthy poultry inMarch 2013 in Eastern China. We evalu-
ated replication, tropism, and cytokine induction of the A/Anhui/1/2013 (H7N9) virus isolated from a fatal human infection and
two low-pathogenic avian H7 subtype viruses in a human lung organ culture systemmimicking infection of the lower respira-
tory tract. The A(H7N9) patient isolate replicated similarly well as a seasonal IAV in explanted human lung tissue, whereas avian
H7 subtype viruses propagated poorly. Interestingly, the avian H7 strains provoked a strong antiviral type I interferon (IFN-I)
response, whereas the A(H7N9) virus induced only low IFN levels. Nevertheless, all viruses analyzed were detected predomi-
nantly in type II pneumocytes, indicating that the A(H7N9) virus does not differ in its cellular tropism from other avian or hu-
man influenza viruses. Tissue culture-based studies suggested that the low induction of the IFN- promoter correlated with an
efficient suppression by the viral NS1 protein. These findings demonstrate that the zoonotic A(H7N9) virus is unusually well
adapted to efficient propagation in human alveolar tissue, which most likely contributes to the severity of lower respiratory tract
disease seen in many patients.
IMPORTANCE Humans are usually not infected by avian influenza A viruses (IAV), but this large group of viruses contributes to
the emergence of human pandemic strains. Transmission of virulent avian IAV to humans is therefore an alarming event that
requires assessment of the biology as well as pathogenic and pandemic potentials of the viruses in clinically relevant models.
Here, we demonstrate that an early virus isolate from the recent A(H7N9) outbreak in Eastern China replicated as efficiently as
human-adapted IAV in explanted human lung tissue, whereas avian H7 subtype viruses were unable to propagate. Robust repli-
cation of the H7N9 strain correlated with a low induction of antiviral beta interferon (IFN-), and cell-based studies indicated
that this is due to efficient suppression of the IFN response by the viral NS1 protein. Thus, explanted human lung tissue appears
to be a useful experimental model to explore the determinants facilitating cross-species transmission of the H7N9 virus to hu-
mans.
Received 1 August 2013 Accepted 23 September 2013 Published 8 October 2013
Citation Knepper J, Schierhorn KL, Becher A, Budt M, Tönnies M, Bauer TT, Schneider P, Neudecker J, Rückert JC, Gruber AD, Suttorp N, Schweiger B, Hippenstiel S, Hocke AC,
Wolff T. 2013. The novel human influenza A(H7N9) virus is naturally adapted to efficient growth in human lung tissue. mBio 4(5):e00601-13. doi:10.1128/mBio.00601-13.
Editor Peter Palese, Icahn School of Medicine at Mount Sinai
Copyright © 2013 Knepper et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported
license, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
Address correspondence to Thorsten Wolff, WolffT@RKI.de.
At least 135 people have been infected with a novel influenzaA(H7N9) virus since February 2013 in Eastern China, resulting
in a high frequency of severe lower respiratory tract infections and 44
fatalities (1, 2). This novel influenza A virus (IAV) most likely
emerged from a zoonotic reservoir, as closely related viruses were
isolated from apparently healthy poultry in those provinces (3). Ge-
nome sequencing indicated that the H7N9 virus derives its genes
fromat least threedifferent low-pathogenicavianIAVstrains (1,4,5).
Affected patients experienced febrile influenza-like illness, rapidly
progressing topneumoniaandacute respiratorydistress syndrome in
many cases, indicating the spread of the virus to the lung (1). The
capacity to infect the lower respiratory tract was also reproduced in
experimental infections of ferrets, pigs,macaques, andmice, which is
unusual for an avian influenza virus (6–9). Recent analyses detected
significantly increased cytokine and chemokine levels in A(H7N9)
patient serum samples, which may reflect a dysregulation of the im-
mune response contributing to the severity of the disease (10). Al-
thoughmany A(H7N9) patients had underlying chronic conditions,
this outbreak challenges the concept that IAVwith lowpathogenicity
in birds infect humans very rarely and do not cause severe disease
(11), raising questions as to the specific properties of this novel zoo-
notic pathogen in humans.
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Genetic analyses showed that novelH7N9 viruses harbor adap-
tive changes associated with enhanced fitness of avian IAV in hu-
man hosts. This includes a glutamine-to-leucine change at posi-
tion 226 (H3 numbering) within the receptor binding site of the
viral hemagglutinin, which most likely extends the spectrum of
virus receptors by enabling binding to avian (alpha-2,3-linked
sialic acid) as well as human (alpha-2,6-linked sialic acid) receptor
determinants (8, 10, 12, 13). Moreover, the presence of lysine and
asparagine at polymorphic amino acid positions 627 and 701, re-
spectively, in the PB2 protein of patient H7N9 isolates indicates
initial adaptation for increased polymerase activity inmammalian
cells (3). However, virulence of IAV is a multigenic trait, and ad-
ditional genetic changes encoding adaptive amino acids may be
present in the novel H7N9 reassortant virus (4). An important
aspect of IAV pathogenicity is the capacity to suppress the innate
antiviral response by means of the viral NS1 protein. This multi-
functional viral factor limits expression of type I interferon
(IFN-I) genes via blockade of the signaling pathway governed by
retinoic acid-induced gene I (RIG-I), silences activation of the
kinase PKR, and prevents fast apoptosis of infected host cells (14).
NS1 proteins of human and avian IAV strains have a length of 215
to 237 amino acids and can differ in their primary sequences by
more than 30%, indicating specific adaptations to the respective
host environment (15). We previously showed that a low-
pathogenic avian IAV (subtype H12N5) was strongly attenuated
for growth in explanted human lung tissue but provoked a strong
cytokine response in comparison to human-adapted seasonal and
pandemic IAV (16). Given the substantial viral loads detected in
lower respiratory tract samples of A(H7N9) patients (3), we
herein compared the replicative potential and activation of innate
responses by an H7N9 patient isolate and two low-pathogenic H7
subtype viruses of the Eurasian lineage in human alveolar tissue.
Replication analysis in primary human lung tissue showed that
theA/Anhui/1/2013 (H7N9) virus propagated similarlywell as the
prototypic human A/Panama/2007/1999 (H3N2) strain over a
48-h period, reaching titers in the range of 105 PFU/ml. In con-
trast, there was hardly any titer increase detectable for two low-
pathogenic avian H7 subtype viruses [A/turkey/Italy/472/1999
(H7N1) and A/turkey/Germany/R11/2001 (H7N7)] after inocu-
lation of tissue from identical donor lungs (Fig. 1A). The differ-
ences between human and avian H7 viruses became highly signif-
icant through the course of infection. Importantly, lung tissue
infectedwith the two avianH7 viruses released significantly higher
levels of antiviral IFN- into the supernatants than the humanH7
virus (Fig. 1B). The levels of secreted MIP-1, IP-10, and inter-
leukin 1 (IL-1) were also slightly higher for the two avian
strains, but those differences were statistically not significant
(Fig. 1C and D and data not shown). Differences in viral growth
and cytokine induction between avian and human H7 strains
might be due to differences in the principal target cells. Therefore,
we examined the cellular tropism of the H7-subtype viruses by
double staining for viral antigen and cell-type-specific markers in
the alveolar tissue. This analysis showed that the human and the
avian H7 strains were detected in type II but not in type I pneu-
mocytes (Fig. 1E and data not shown), indicating that those vi-
ruses target the same host cell type as was previously shown for
other avian, porcine, and human IAV (16).
Growth curve analyses inmammalian and avian cell lines dem-
onstrated that the human H7N9 strain propagated more effi-
ciently than the avian H7 viruses in human (A549) and canine
(MDCK) cells (Fig. 2A and C), whereas there was a more equal
growth kinetic in chicken DF1 fibroblasts (Fig. 2B). This result
points again toward an unusually high inherent capacity of the
H7N9 virus to propagate in mammalian cells. Since the two avian
H7 strains provoked significantly higher levels of IFN- in the
lung cultures, we next evaluated activation of the human IFN-
promoter and the suppression of this response by the NS1 pro-
teins expressed by the different strains. Figure 2D illustrates that
NS1-deficient human virus strongly activated a stably integrated
human IFN- promoter by more than 45-fold, whereas the iso-
genic wild-type virus stimulated the promoter only by about
3-fold, illustrating the pivotal role of NS1 in IFN suppression
(Fig. 2D). The three H7 strains induced the IFN- promoter also
to a small extent, but the A/Anhui/1/2013 (H7N9) strain was the
least active one. Finally, we tested the capacity of transiently ex-
pressed NS1 proteins to block RIG-I-dependent upregulation of
the IFN- promoter in human cells infected with NS1-deficient
virus. The analysis showed that expression of the hu-H7NS1 gene
suppressed viral activation of the IFN- promoter significantly
stronger than the avian NS1 proteins, whereas NS1 of the epi-
demic H3 strain had intermediate activity (Fig. 2E). These results
suggest that the NS1 protein of the novel H7N9 virus is a potent
inhibitor of the antiviral human IFN response and may thereby
contribute to its intriguingly strong replication in human alveolar
tissue.
The isolation of avian A(H7N9) virus from a substantial num-
ber of pneumonia patients was unexpected and is amajor cause of
concern, even if the virus has not yet acquired the ability for sus-
tained transmission among humans. A total of 16 of the 17 sub-
types of the IAV hemagglutinin are found in feral birds (17).
Among humans, only viruses of theH1,H2, andH3 subtypes have
circulated to larger extents, rendering most of the human popu-
lation in principle vulnerable to infection with other subtypes.
However, transmission of avian IAV to humans occurs rarely, as
those viruses usually lack adaptive changes that would enable ef-
ficient propagation and spread among humans (18). Here, we
describe an experimental model for the A(H7N9) virus in human
alveolar lung tissue infected ex vivo that complements recent anal-
yses of this virus in animalmodels (6–9). As the lung organ culture
system revealed clear differences between bona fide avian and
human-adapted strains, this approach appears useful to evaluate
the zoonotic potential of IAV. Our initial assessment demon-
strated that the human A(H7N9) virus is as adapted to efficient
growth in human lung tissue as a prototypic epidemic virus strain,
whereas this tissue was essentially nonpermissive for two avianH7
isolates. The restriction of the avian viruses is most likely not me-
diated on the level of virus entry, as infected alveolar cells were
easily identified in tissue sections for all strains examined and
there was no apparent change in the preference to infect type II
pneumocytes. This finding is consistent with the presence of re-
ceptors for both human and avian IAV cells in human alveolar
tissue and recapitulates that receptor specificity is not a decisive
determinant of influenza virus tropism in the lower respiratory
tract (16). Productive IAV infection of type II pneumocytes and
resulting cytopathic effects are expected to compromise alveolar
structural integrity by reducing the production of surfactant and
to diminish the repair capacity of the injured lung (19, 20).
The humanAnhui/1/2013 virus displays an adaptive lysine (K)
residue at PB2 position 627, whereas this position is occupied by a
glutamic acid (E) in the avian H7 strains. Notably, the human H7
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strain induced significantly lower levels of antiviral IFN than the
avian H7 viruses, which in combination with the PB2 E627K
change may explain its robust growth. In fact, our analysis sug-
gests that the NS1 protein encoded by the human H7 isolate is a
potent inhibitor of RIG-I-dependent activation of IFN-I genes.
The NS1 protein is well known to contribute to influenza A virus
pathogenicity and virulence (21, 22). The primary NS1 sequence
of the Anhui/1/2013 strain shows conserved residues at positions
known to be important for IFN suppression, such as R38 andK41,
but it lacks several other motifs present in NS1 proteins of other
IAVs which mediate binding to host factors. This includes the
C-terminal 4-amino-acid binding motif for cellular PDZ domain
factors (23) as well as residues facilitating interaction with CPSF-
30, which is involved in the maturation of cellular transcripts,
including IFN- pre-mRNA (24). Clearly, the significance of spe-
cific amino acid residues of the H7N9-Anhui NS1 protein and
other viral polypeptides for replication and cytokine control in
human respiratory tissues will need to be examined in future re-
FIG 1 Efficient replication, cytokine induction, and cellular tropism of H7N9 virus in human lung tissue infected ex vivo. Tumor-free normal lung tissue was
stamped into small cylinders (thickness of ~3 mm, diameter of 8 mm) and incubated in RPMI 1649 medium (containing 0.3% bovine serum albumin [BSA],
2 mM glutamine, and antibiotics) at 37°C with 5% CO2 as described (16). After overnight incubation, lung organ cultures were inoculated with 4 105 (A) or
4 106 (B to E) PFU of the influenza A viruses A/Anhui/1/2013 (hu-H7), A/Turkey-Italy/472/1999 (av-H7-It), or A/Turkey-Germany/R11/2001 (av-H7-Ger)
for 1 h, followed by being washed with phosphate-buffered saline (PBS) to remove excess virus and incubation in RPMI 1649 medium at 37°C. The epidemic
influenza A/Panama/2007/1999 virus (hu-H3) was included as a control. For each experiment, tumor-free tissue specimens from at least three donors were
analyzed. Stocks of the avian H7 viruses were grown in embryonated chicken eggs, whereas the human H3 and H7 viruses were propagated in MDCK cells to
minimize selection of receptor binding variants. (A)Aliquots of supernatants taken at 0, 16, 24, and 48 hpostinfection (hpi)were titrated by standard plaque assay
on MDCK cells. The relative growth of the strains is depicted as titer increase compared to the start of infection (0 hpi). The human H7 strain propagated as
efficiently as the seasonal human virus, whereas the two avian H7 viruses hardly replicated. Mean values and standard errors of the means (SEM) from 3
independent experiments each done in triplicate are shown. Asterisks indicate significant differences between strains (Mann-Whitney U test; *, P 0.05; **, P
 0.01; ***, P 0.001). (B to D) Aliquots of infected lung culture supernatant taken at 24 or 48 hpi were analyzed for the concentrations of IFN- (B), MIP-1
(C), or IP-10 (D) by commercial enzyme-linked immunosorbent assay (ELISA) kits (FUJIREBIO Inc., Invitrogen, BD Biosciences). Data points from four
independent experiments are shown individually, and mean values are indicated (line). Significance values between groups are indicated by asterisks (Mann-
WhitneyU test; *, P 0.05). The humanH7 virus induced significantly less IFN- than av-H7-It and av-H7-Ger. (E) Conserved tropism of H7-subtype viruses
for type II pneumocytes. Human lung tissue was not infected (mock) or was infected with hu-H7 or av-H7-Ger for 24 h. The tissue samples were fixed and
routinely paraffin embedded as described (16). After deparaffinization and antigen retrieval, slices were immunostained with fluorescently (Alexa Fluor 488)
labeled anti-influenza A virus antibody (Serotec; OBT1551) (green channel) to detect virus-infected cells (white arrowheads). The slices were costained with
rabbit antibodies detecting either pro-SP-C (Chemicon; AB3786; top row) or EMP2 (Sigma; HPA014711; bottom row) to identify type II or type I pneumocytes
(red channels), respectively. An Alexa Fluor 594-labeled anti-rabbit F(ab=)2 fragment was applied as the secondary antibody. Nuclei (blue) were counterstained
with DAPI (4=,6-diamidino-2-phenylindole). Open arrowheads identify noninfected cells. Immunofluorescence was analyzed by spectral confocal microscopy
and linear unmixing of tissue autofluorescence by using a 780 laser-scanning microscope (objective, 40/1.30 oil differential inference contrast [DIC] M27).
Scale bar, 10 m.
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FIG 2 Efficient replication of the H7N9 virus in mammalian cell lines correlates with low activation of the human IFN- promoter. (A to C) Multicyclic
replication of the virus strains A/Anhui/1/2013 (hu-H7), A/Turkey-Italy/472/1999 (av-H7-It), A/Turkey-Germany/R11/2001 (av-H7-Ger), and A/Panama/
2007/1999 (hu-H3) was determined in cultures of human A549 lung epithelial cells (A), in chicken DF1 fibroblasts (B), and in canineMDCK epithelial cells (C).
Cells were infected with the indicated viruses (multiplicity of infection [MOI] 0.01) and were incubated at 37°C in the presence of trypsin for 72 h. Aliquots
taken at the indicated points were titrated on MDCK cells by using a standard plaque assay. The graphs show mean values and SEM from 3 independent
experiments, each donewith biological duplicates.Dashed lines indicate the limit of detection.Hu-H7 replicated as efficiently onA549 andMDCKcells as hu-H3,
whereas av-H7 viruses were impaired in growth by about 100-fold. On DF1 cells, the viruses showed less variable replication. (D) MDCK cells with a stably
integrated human IFN- promoter luciferase reporter were mock treated or infected with hu-H7, hu-H3, or two av-H7 viruses for 12 h (MOI 1). We used an
isogenicNS1-deletedH3N2 (hu-H3NS1)mutant virus to determine reporter activation in the absence of a viral IFN antagonist (25). Cells were lysed, and equal
amounts of protein were analyzed by luciferase assay (3 experiments conducted in triplicate each, mean SEM; top). Expression of viral NP and NS1 proteins
and cellular actin as the loading control was verified by immunoblotting (bottom). Infection with hu-H3 (NS1) caused a strong activation of the IFN-
promoter, whereas a modest induction was observed for all other viruses. (E) NS1 expression plasmids were constructed by placing viral NS cDNA of the
indicated strains under the control of the human cytomegalovirus immediate early promoter. Human 293T cells were transfected for 24 h with an IFN-
promoter reporter plasmid, FLAG-RIG-I, and pRL-TK, expressing a renilla luciferase under the control of the constitutive herpes simplex virus (HSV) tk
promoter for normalization and an NS1 expression construct from the indicated virus strain as described (25). Empty vector was used as the control. Where
indicated, samples were infected for 16 h with NS1-deficient influenza virus (MOI  1). IFN- induction was determined by dual-luciferase assays (n  3 in
triplicates, mean SEM; *, P 0.05; Mann-Whitney U test). Hu-H7 NS reduced IFN- promoter activity significantly stronger than avian H7 strains.
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verse genetic analyses. Possibly, only a small number of additional
mutations or reassortment events with a human virus strain may
increase the potential for enhanced transmission of H7N9-like
viruses. Considering the unknown extent of H7N9 circulation in
domestic and feral birds and the high case fatality rate in vulner-
able humans, it appears important to maintain a high level of
surveillance and vigilance for these viruses in the human and an-
imal health sectors.
This studywas approved by the ethics committee at theCharité
clinic (projects EA2/050/08 and EA2/023/07).
Nucleotide sequence accession numbers. Sequence informa-
tion for the NS and PB2 segments of the av-H7-It and av-H7-Ger
strains has been deposited at the GISAID sequence database (http:
//platform.gisaid.org; accession no. EPI464812, EPI464813,
EPI467219, and EPI467220).
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